

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
1662/604078

Application Number
10/635,337

Filing Date
August 6, 2003

Examiner
Not Yet Known

Art Unit
1614

Invention Title
**NOVEL CRYSTALLINE FORMS OF
GATIFLOXACIN**

Inventors
NIDDAM-HILDESHEIM et al.

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited
with the United States Postal Service with sufficient postage
as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450 on

Date: 5/6/04 Reg. No. _____

Signature: Catherine Edwards


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: May 6, 2004

By: John B. Starr, Jr.
John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
1662/604078

Application Number
10/635,337

Filing Date
August 6, 2003

Examiner
Not Yet Known

Art Unit
1614

Invention Title
**NOVEL CRYSTALLINE FORMS OF
GATIFLOXACIN**

Inventors
NIDDAM-HILDESHEIM et al.

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited
with the United States Postal Service with sufficient postage
as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450 on

Date: 5/6/04 Reg. No. _____

Signature: Catherine [Signature]


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: May 6, 2004

By: John B. Starr, Jr.
John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./



**INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT
PTO-1449**

ATTY. DOCKET NO.
1662/604078

SERIAL NO.
10/635,337

APPLICANT
NIDDAM-HILDESHEIM et al.

FILING DATE
August 6, 2003

GROUP
1614

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02 22126	March 21, 2002	EPO				
	EP 0 805 156 A	November 5, 1997	EPO				
	EP 0 629 621 A	December 21, 1994	EPO				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	/Paul Ward/ (02/26/2008)	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./